4.54
+0.89%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lexaria Bioscience
From its filings with the US Securities and Exchange Commission
Lexaria Bioscience is based in Kelowna, British Columbia, Canada and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker LEXX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 August 2025, it reported revenue of $705,923 and a net loss of $11.9m. At that date it held total assets of $4.2m and shareholders' equity of $3.0m.
Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs (“GLP-1”) and glucose-dependent insulinotropic polypeptide drugs (“GIP”), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
Quoted from its 10-K, filed 28 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Oct 2009
- Employees
- 5
- Website
- lexariabioscience.com ↗
- Head office
- 100 - 740 MCCURDY ROAD, KELOWNA, A1, V1X 2P7
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Christopher BunkaChairman of the Board, since 2006$884,844
- Mr. John DochertyPresident, Director, since 2015$414,415
- Mr. Richard ChristopherChief Executive Officer$519,317
- Mr. Michael ShankmanChief Financial Officer
- Mr. Nicholas BaxterIndependent Director$74,828
- Mr. William MckechnieIndependent Director$69,828
- Mr. Albert ReeseIndependent Director$74,828
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 5 full-time employees
- Operates through two segments: Intellectual Property and Products
- Holds 35 patents granted and many patents pending worldwide
Weaknesses
- Company is headquartered in Kelowna, British Columbia
- IPO occurred in 2009-10-28
- Company operates a licensed in-house research laboratory
Opportunities
- DehydraTECH technology improves bioavailability of active pharmaceutical ingredients
- DehydraTECH demonstrated enhanced delivery into brain tissue
- Developed DehydraTECH formulations for intraoral and topical administration
Threats
- Company is a biotechnology firm with limited employee count
- Source description treats facts as untrusted
- Company operates in the Pharmaceuticals sector
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.